"Many people with obesity suffer from co-morbidities," said Novo Nordisk's chief science officer Mads Krogsgaard Thomsen, in a statement. "Saxenda has the potential to help some of these people ...

The NICE recommendation coincided with Novo Nordisk’s third quarter results statement, which showed modest 3% growth for Saxenda in the first nine months of the year to DKK 4.2 billion ($661 ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications including Wegovy, Rybelsus, and Saxenda. You'd think with such a robust ...

Liraglutide is currently sold only in an injectable form under the brand names Saxenda® and Victoza®, both manufactured by Novo Nordisk®. Despite the launch of a genericized injected version of ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies, ...